HCmed Innovations (HCmed), a Taiwanese company specializing in the development of vibrating mesh nebulizers, today announced the successful completion of the first development milestone under its collaboration agreement with CSL Behring.
Earlier this year, CSL Behring, the global leader in biotherapeutics, partnered with HCmed to develop a combination product consisting of a plasma-derived immunoglobulin formulation (CSL787) administered via a customized version of the AdheResp nebulizer, HCmed’s breath-activated mesh nebulizer. As HCmed has now completed the development of the bespoke device to meet the aerosol performance requirements, HCmed will receive the first milestone payment under the partnership. This is a significant achievement for HCmed’s newly developed AdheResp breath-actuated platform, proving that HCmed’s mesh platform is fully capable of delivering biologics via an airway with superior quality and at an affordable cost.
Inhaled forms of immunoglobulins will potentially expand delivery options, and because nebulized therapy can be self-administered by patients, the need for healthcare resources may also be reduced. In addition, the way patients receive inhaled therapies in the future will gradually change with the introduction of respiratory-driven nebulizers. With this function the nebulizers produce aerosol only in response to the patient’s inhalation, reducing the loss of medication on exhalation. This feature makes respiratory-driven nebulizers a desirable device for aerosolizing high-value therapeutic medications.
“This represents another step forward in the development of novel mesh nebulizers for easier administration of plasma-derived immunoglobulins,” shared HCmed CEO, Jason Cheng. “Together with CSL Behring, we are committed to providing affordable and effective treatment options to patients suffering from respiratory diseases, and this milestone brings us closer to achieving our goal.”
